Skip to main
SBRA

SBRA Stock Forecast & Price Target

SBRA Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 27%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Sabra Health Care REIT is well positioned for strong growth in the healthcare REIT sector due to high demand for these facilities driven by demographics and limited new supply. The company's recent announcements, including the re-tenancy of all its Avamere properties at a 30% premium and increased rent for smaller tenants, point to a strong operating performance. Additionally, the recent repayment and forgiveness of a $300 million mortgage loan will strengthen Sabra's balance sheet and allow for more attractive investment opportunities. These developments, combined with a positive outlook for senior housing and skilled nursing fundamentals, make Sabra a solid investment choice in the healthcare REIT space.

Bears say

Sabra Health Care REIT is facing challenges as their recent portfolio initiatives show a relatively small increase in cash NOI compared to the same period last year, and the transition of all properties leased by Avamere to Cascadia Healthcare is concerning, given the latter's previous unsuccessful takeovers. Additionally, the increase in G&A expenses and lower cash NOI growth projections for the triple-net portfolio and SHOP portfolio raises concerns about the company's future financial performance.

SBRA has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 27% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sabra Health Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sabra Health Care (SBRA) Forecast

Analysts have given SBRA a Hold based on their latest research and market trends.

According to 11 analysts, SBRA has a Hold consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sabra Health Care (SBRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.